• 7023 malaria professionals are enjoying the free benefits of MalariaWorld today

Artemisinin

Open Access | Editorial: How Do We Best Diagnose Malaria in Africa?

Author(s): 
Philip J. Rosenthal
Reference: 
Am J Trop Med Hyg 2012 86:192-193
Contact email: 
prosenthal@medsfgh.ucsf.edu

MalariaWorldIn this regard, the advent of rapid diagnostic tests (RDTs) for malaria is an important advance. Multiple immunochromatographic tests, incorporating a number of different parasite antigens and produced by many different manufacturers, are now available.

Clinical Study: Risk Factors for Gametocyte Carriage in Uncomplicated Falciparum Malaria in Children before and after Artemisinin-Based Combination Treatments

Author(s): 
Akintunde Sowunmi, Titilope M. Okuboyejo, Grace O. Gbotosho, Christian T. Happi
Reference: 
Chemotherapy 2011;57:497-504
Contact email: 
akinsowunmi@hotmail.com

MalariaWorldThe risk factors associated with gametocytaemia at presentation and after ACTs were evaluated in 835 children assigned to artesunate, artesunate-amodiaquine, artesunate-mefloquine or artemether-lumefantrine.

Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin

Author(s): 
Patrick J. Westfall, Douglas J. Pitera, Chris J. Paddon, et al.
Reference: 
PNAS January 17, 2012 vol. 109 no. 3 E111-E118
Contact email: 
newman@amyris.com

MalariaWorldMalaria, caused by Plasmodium sp, results in almost one million deaths and over 200 million new infections annually.

Open Access | The use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel

Author(s): 
Agnandji ST, Kurth F, Ramharter M, et al.
Reference: 
Malaria Journal 2011, 10:365 (14 December 2011)
Contact email: 
agnandjis@lambarene.org

http://www.pnas.org/content/108/50/20113.abstractThis snapshot questionnaire survey aimed to provide an overview on the current routine practices for the availability and use P-ACT as anti-malarial treatment for young children in sub-Saharan Africa.

Open Access | Prescription practices and availability of artemisinin monotherapy in India: where do we stand?

Author(s): 
Mishra N, Anvikar AR, Shah NK, Kamal V, Sharma S, Srivastava H, Das M, Pradhan K, Kumar H, Gupta YK, Gupta P, Dash A, Valecha N
Reference: 
Malaria Journal 2011, 10:360 (13 December 2011)
Contact email: 
neelima@mrcindia.org

MalariaWorldThis study resulted in notifications to all state drug controllers in India to withdraw the oral artemisinin formulations from the market. In 2010, artesunate + sulphadoxine-pyrimethamine became the universal first-line treatment for confirmed Plasmodium falciparum malaria and was deployed at full scale.

Generation of the potent anti-malarial drug artemisinin in tobacco

Author(s): 
Moran Farhi, Elena Marhevka, Julius Ben-Ari, Anna Algamas-Dimantov, Zhuobin Liang, Vardit Zeevi, Orit Edelbaum, Ben Spitzer-Rimon, Hagai Abeliovich, Betty Schwartz, Tzvi Tzfira and Alexander Vainstein
Reference: 
Nature Biotechnology, Volume: 29,Pages: 1072–1074 Year published:(2011)
Contact email: 
vain@agri.huji.ac.il

MalariaWorldThe emergence of multidrug-resistant strains of Plasmodium spp., the etiological agent of malaria, constitutes a major threat to controlling the disease1, 2.

Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study

Author(s): 
Jean-François Trape, Adama Tall, Cheikh Sokhna, et al.
Reference: 
The Lancet Infectious Diseases, Volume 11, Issue 12, December 2011, Pages 925-932
Contact email: 
jean-francois.trape@ird.fr

MalariaWorldWe did a longitudinal study of inhabitants of Dielmo village, Senegal, between January, 2007, and December, 2010. We monitored the inhabitants for fever during this period and we treated malaria attacks with artesunate plus amodiaquine.

Malaria drug resistance: new observations and developments.

Author(s): 
Sá JM, Chong JL, Wellems TE
Reference: 
Essays Biochem. 2011 Oct 24;51:137-60.
Contact email: 
twellems@niaid.nih.gov

MalariaWorldWe review some contributions that early efficacy studies of antimalarial treatment brought to clinical pharmacology, including convincing documentation of atebrine-resistant malaria in the 1940s, prior to the launching of what soon became first-choice antimalarials, chloroquine and amodiaquine.

Open Access | Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis

Author(s): 
Liu R, Dong H, Guo Y, Zhao Q, Jiang M
Reference: 
Parasites & Vectors 2011, 4:201 (17 October 2011)
Contact email: 
liurong19840901@whu.edu.cn

MalariaWorldIn this article, we conducted a systematic review and meta-analysis to evaluate the antischistosomal efficacy of different medication strategies including monotherapy or combination therapies of these drugs.
 

Open Access | In vitro anti-plasmodial activity of Dicoma anomala subsp. gerrardii (Asteraceae): identification of its main active constituent, structure-activity relationship studies and gene expression profiling

Author(s): 
Becker JV, van der Merwe MM, Van Brummelen AC, Pillay P, Crampton BG, Mmutlane EM, Parkinson C, van Heerden FR, Crouch NR, Smith PJ, Mancama DT, Maharaj VJ
Reference: 
Malaria Journal 2011, 10:295 (11 October 2011)
Contact email: 
jbecker@csir.co.za

MalariaWorldThe novel mode of action of dehydrobrachylaenolide, detected during these studies, will play an ongoing role in advancing anti- plasmodial drug discovery efforts.

Syndicate content